|New Data Support the Benefits of EXPAREL for Postsurgical Analgesia Following Aesthetic Plastic Surgery Procedures|
Results Presented at
“When considering an elective procedure, postsurgical pain ranks high on
the list of patient concerns, and adequate pain management during the
first few days after surgery—when pain is at its worst—is crucial to a
patient’s overall satisfaction with the surgeon and the procedure,” said
The EXCLAIM study encompassed a total of 49 patients evaluated from 10 sites nationwide. In the immediate postsurgical setting and for three days following their procedure, patients were asked to rate their pain intensity and satisfaction with pain management, as well as report the number of opioids taken as rescue medication and the impact any associated opioid-related adverse events had on their quality of life.
Key findings demonstrated that patients treated with EXPAREL reported:
“Apprehension about postsurgical pain can make patients hesitant to
proceed with cosmetic plastic surgery, especially when considering
procedures such as abdominoplasty that are often thought of as being
associated with significant discomfort and downtime after surgery,”
EXPAREL is the first and only single-dose local analgesic that provides
pain control with reduced opioid requirements for up to 72 hours. It was
approved for administration into the surgical site to produce
postsurgical analgesia by the
The study findings will be presented at the Hot Topics session of the
Aesthetic Meeting 2013 on
EXPAREL (bupivacaine liposome injectable suspension) is indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. The product combines bupivacaine with DepoFoam, a proven product delivery technology that delivers medication over a desired time period. EXPAREL represents the first and only multivesicular liposome local anesthetic that can be utilized in the peri- or postsurgical setting in the same fashion as current local anesthetics. By utilizing the DepoFoam platform, a single dose of EXPAREL delivers bupivacaine over time, providing analgesia with reduced opioid requirements for up to 72 hours. Pivotal studies have demonstrated the safety and efficacy of EXPAREL in patients undergoing bunionectomy or hemorrhoidectomy procedures and additional studies are underway to further demonstrate the safety and efficacy in other procedures. Additional information is available at www.EXPAREL.com.
Important Safety Information
EXPAREL is contraindicated in obstetrical paracervical block anesthesia. EXPAREL has not been studied for use in patients younger than 18 years of age. Non-bupivacaine-based local anesthetics, including lidocaine, may cause an immediate release of bupivacaine from EXPAREL if administered together locally. The administration of EXPAREL may follow the administration of lidocaine after a delay of 20 minutes or more. Other formulations of bupivacaine should not be administered within 96 hours following administration of EXPAREL. Monitoring of cardiovascular and neurological status, as well as vital signs should be performed during and after injection of EXPAREL as with other local anesthetic products. Because amide-type local anesthetics, such as bupivacaine, are metabolized by the liver, EXPAREL should be used cautiously in patients with hepatic disease. Patients with severe hepatic disease, because of their inability to metabolize local anesthetics normally, are at a greater risk of developing toxic plasma concentrations. In clinical trials, the most common adverse reactions (incidence greater-than or equal to 10%) following EXPAREL administration were nausea, constipation, and vomiting.
Please see the full Prescribing Information for more details available at http://www.exparel.com/pdf/EXPAREL_Prescribing_Information.pdf.